Catalogue Search | MBRL
Are you sure you want to remove the book from the shelf?
{{itemTitle}}
56,346
result(s) for
"General Cardiology"
Sort by:
The man who touched his own heart : true tales of science, surgery, and mystery
Tells the raucous, gory, mesmerizing story of the heart, from the first \"explorers\" who dug up cadavers and plumbed their hearts' chambers, through the first heart surgeries-which had to be completed in three minutes before death arrived-to heart transplants and the latest medical efforts to prolong our hearts' lives, almost defying nature in the process. Thought of as the seat of our soul, then as a mysteriously animated object, the heart is still more a mystery than it is understood. Why do most animals only get one billion beats? (And how did modern humans get to over two billion-effectively letting us live out two lives?) Why are sufferers of gingivitis more likely to have heart attacks? Why do we often undergo expensive procedures when cheaper ones are just as effective? What do Da Vinci, Mary Shelley, and contemporary Egyptian archaeologists have in common? And what does it really feel like to touch your own heart, or to have someone else's beating inside your chest? Rob Dunn's fascinating history of our hearts brings us deep inside the science, history, and stories of the four chambers we depend on most.
Book
NEJM at ESC — Plozasiran for Managing Persistent Chylomicronemia and Pancreatitis Risk
In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 European Society of Cardiology annual meeting. . . .
Journal Article
NEJM at AHA — Left Atrial Appendage Closure after Ablation for Atrial Fibrillation
In this audio interview, Editor-in-Chief Eric Rubin and Deputy Editor Jane Leopold discuss research being presented at the 2024 American Heart Association Scientific Sessions. . . .
Journal Article
Long Covid Defined
Long Covid DefinedMembers of the National Academies of Sciences, Engineering, and Medicine describe the process and rationale for the development of the 2024 definition of persistent Covid-19 symptoms (long Covid).
Journal Article
Efficacy and Safety of an Extravascular Implantable Cardioverter–Defibrillator
In a prospective global study, extravascular implantable cardioverter–defibrillators with a substernal lead were implanted safely and were able to detect and terminate induced ventricular arrhythmias at the time of implantation.
Journal Article
Patisiran Treatment in Patients with Transthyretin Cardiac Amyloidosis
Transthyretin amyloidosis, also called ATTR amyloidosis, is associated with accumulation of ATTR amyloid deposits in the heart and commonly manifests as progressive cardiomyopathy. Patisiran, an RNA interference therapeutic agent, inhibits the production of hepatic transthyretin.
In this phase 3, double-blind, randomized trial, we assigned patients with hereditary, also known as variant, or wild-type ATTR cardiac amyloidosis, in a 1:1 ratio, to receive patisiran (0.3 mg per kilogram of body weight) or placebo once every 3 weeks for 12 months. A hierarchical procedure was used to test the primary and three secondary end points. The primary end point was the change from baseline in the distance covered on the 6-minute walk test at 12 months. The first secondary end point was the change from baseline to month 12 in the Kansas City Cardiomyopathy Questionnaire-Overall Summary (KCCQ-OS) score (with higher scores indicating better health status). The second secondary end point was a composite of death from any cause, cardiovascular events, and change from baseline in the 6-minute walk test distance over 12 months. The third secondary end point was a composite of death from any cause, hospitalizations for any cause, and urgent heart failure visits over 12 months.
A total of 360 patients were randomly assigned to receive patisiran (181 patients) or placebo (179 patients). At month 12, the decline in the 6-minute walk distance was lower in the patisiran group than in the placebo group (Hodges-Lehmann estimate of median difference, 14.69 m; 95% confidence interval [CI], 0.69 to 28.69; P = 0.02); the KCCQ-OS score increased in the patisiran group and declined in the placebo group (least-squares mean difference, 3.7 points; 95% CI, 0.2 to 7.2; P = 0.04). Significant benefits were not observed for the second secondary end point. Infusion-related reactions, arthralgia, and muscle spasms occurred more often among patients in the patisiran group than among those in the placebo group.
In this trial, administration of patisiran over a period of 12 months resulted in preserved functional capacity in patients with ATTR cardiac amyloidosis. (Funded by Alnylam Pharmaceuticals; APOLLO-B ClinicalTrials.gov number, NCT03997383.).
Journal Article
Spontaneous Intracerebral Hemorrhage
Spontaneous brain hemorrhages result from chronic hypertension, anticoagulation, or amyloid angiopathy. Tissue disruption from the hematoma can be followed by brain edema and expansion of the clot that worsen prognosis.
Journal Article
Pulmonary Arterial Hypertension
Without effective treatment, pulmonary arterial hypertension results in high morbidity and mortality. This review discusses the pathogenesis of the disorder, the thorough clinical evaluation required to establish the diagnosis, available therapies, and future directions.
Journal Article